Max Robotics — Global Service Robot Directory + US Certification

About

Bodil Andersson is a leading surgical oncologist whose research focuses on improving outcomes for pancreatic cancer patients through innovative preclinical models and international benchmarking of surgical techniques. Her most cited work introduces organoid technology as a platform for personalized pancreatic cancer therapy, offering a powerful new tool to test drug responses and overcome the historically stagnant survival rates of pancreatic ductal adenocarcinoma—a disease with the lowest survival among major cancers. This paper, with 30 citations, underscores her commitment to bridging the gap between laboratory models and clinical reality. Dr. Andersson is also at the forefront of global efforts to standardize and evaluate pancreatic surgery. Through a series of transatlantic analyses using large international registries, she has compared the use and outcomes of minimally invasive versus open distal pancreatectomy and pancreatoduodenectomy across North America and Europe. Her work on defining the “Ideal Outcome” after left pancreatectomy provides a composite measure to holistically assess surgical quality. By harmonizing European and American metrics, she is helping to set new standards for safety and effectiveness in pancreatic surgery, directly informing how surgeons select patients and measure success.